Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Net Income (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Net Income data on record, last reported at -$65.2 million in Q4 2025.

  • For Q4 2025, Net Income fell 33.13% year-over-year to -$65.2 million; the TTM value through Dec 2025 reached -$263.5 million, down 59.62%, while the annual FY2025 figure was -$263.5 million, 59.62% down from the prior year.
  • Net Income reached -$65.2 million in Q4 2025 per OCUL's latest filing, up from -$68.0 million in the prior quarter.
  • Across five years, Net Income topped out at -$19.5 million in Q1 2022 and bottomed at -$68.0 million in Q3 2025.
  • Average Net Income over 5 years is -$34.4 million, with a median of -$22.9 million recorded in 2022.
  • Peak YoY movement for Net Income: grew 10.95% in 2022, then crashed 115.52% in 2024.
  • A 5-year view of Net Income shows it stood at -$19.7 million in 2021, then dropped by 5.38% to -$20.8 million in 2022, then dropped by 9.42% to -$22.7 million in 2023, then plummeted by 115.52% to -$49.0 million in 2024, then tumbled by 33.13% to -$65.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$65.2 million in Q4 2025, -$68.0 million in Q3 2025, and -$67.2 million in Q2 2025.